Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy

Koch, R.; Principe, Daniel R.; Cataneo, Jose L.; Rana, Ajay

doi:10.3390/cancers13112543

Cited by 5 publications

(5 citation statements)

References 83 publications

(115 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[2,26] Delving deeper into the intricacies of the disease, it becomes evident that the tumor microenvironment (TME) in IBC, encompassing inflammatory and immune cells, blood vessels, and the extracellular matrix, is pivotal to the disease's pathogenesis and aggressive behavior. [27,28] The elaborate interplay between the intrinsic and extrinsic components of IBC, orchestrated by a myriad of cytokines and chemokines, significantly contributes to the tumor's robust aggressiveness and angiogenic potential. [29] In addition, despite IBC having a unique clinical presentation that distinguishes it from non-IBC forms, the precise molecular mechanisms underpinning the disease remain elusive.…”

Section: Resultsmentioning

confidence: 99%

“…This variation highlights the necessity for conducting clinical trials specifically designed for IBC. [39] The tumor microenvironment in IBC significantly contributes to the disease's aggressive nature and resistance to conventional treatment modalities. [40,41] The intricate interplay between intrinsic and extrinsic factors within the tumors.…”

Section: Discussionmentioning

confidence: 99%

“…[2] The distinct clinical and diagnostic characteristics of IBC emphasize the challenge of managing this aggressive disease and underscore the necessity for improved diagnostic tools and therapeutic strategies rooted in extensive scientific research and clinical trials. [5]…”

Section: Clinical and Diagnostic Characteristics Of Inflammatory Brea...mentioning

confidence: 99%

See 2 more Smart Citations

Current Challenges and Future Directions in the Management of Inflammatory Breast Cancer: A Review

Izzo,

Polistena

et al. 2023

Preprint

View full text Add to dashboard Cite

(1) Background: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer that poses unique management challenges. This review aims to synthesize the current literature on IBC, focusing on diagnosis, treatment, and prognosis, while highlighting recent advances and ongoing issues in patient management.; (2) Methods: We outline the typical clinical presentation and diagnostic criteria of IBC. Additionally, we detail the main therapeutic strategies, including neoadjuvant chemotherapy, surgery, radiation therapy, targeted therapies, hormonal therapies, and emerging treatments such as immunotherapy. The review is based on a comprehensive analysis of the existing literature.; (3) Results: Despite advancements in systemic therapy and a better understanding of IBC biology, the prognosis for patients with IBC remains poor. The overall survival rate has shown only marginal improvement over the past few decades. Future research directions, including the identification of novel biomarkers for early detection and personalized medicine strategies, are identified. The need for more high-quality clinical trials to address the challenges in IBC management is emphasized.; (4) Conclusions: Managing IBC is a complex task that necessitates multidisciplinary care and patient-centered communication. This review provides clinicians and researchers with a comprehensive overview of the current challenges and future directions in IBC management. The goal is to guide treatment decisions and inform further research, ultimately improving patient outcomes and prognosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Current Challenges and Future Directions in the Management of Inflammatory Breast Cancer: A Review

Izzo,

Polistena

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The poor prognosis of this disease is linked to the late stage at which inflammatory breast cancer (IBC) is typically detected. These factors, combined with the absence of treatments specifically designed for IBC, contribute to the poor prognosis associated with the disease [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

Influence of Macrophages on Vascular Invasion of Inflammatory Breast Cancer Emboli Measured Using an In Vitro Microfluidic Multi-Cellular Platform

Gadde,

Mehrabi-Dehdezi,

Debeb

et al. 2023

Cancers

View full text Add to dashboard Cite

Inflammatory breast cancer (IBC) is an aggressive disease with a poor prognosis and a lack of effective treatments. It is widely established that understanding the interactions between tumor-associated macrophages (TAMs) and the tumor microenvironment is essential for identifying distinct targeting markers that help with prognosis and subsequent development of effective treatments. In this study, we present a 3D in vitro microfluidic IBC platform consisting of THP1 M0, M1, or M2 macrophages, IBC cells, and endothelial cells. The platform comprises a collagen matrix that includes an endothelialized vessel, creating a physiologically relevant environment for cellular interactions. Through the utilization of this platform, it was discovered that the inclusion of tumor-associated macrophages (TAMs) led to an increase in the formation of new blood vessel sprouts and enhanced permeability of the endothelium, regardless of the macrophage phenotype. Interestingly, the platforms containing THP-1 M1 or M2 macrophages exhibited significantly greater porosity in the collagen extracellular matrix (ECM) compared to the platforms containing THP-1 M0 and the MDA-IBC3 cells alone. Cytokine analysis revealed that IL-8 and MMP9 showed selective increases when macrophages were cultured in the platforms. Notably, intravasation of tumor cells into the vessels was observed exclusively in the platform containing MDA-IBC3 and M0 macrophages.

show abstract

“…The poor efficacy of ICIs for the treatment of HR + breast cancer may be, in part, due to the limited immune cell infiltrate in these tumors ( 115 ). The effects of ICIs are also currently being examined for the treatment of inflammatory breast cancer ( 116 ). A Phase II study (NCT02411656) is currently assessing the effects of pembrolizumab in metastatic or recurrent inflammatory breast cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer

et al. 2022

View full text Add to dashboard Cite

Breast cancer is the most prevalent non-skin cancer diagnosed in females and developing novel therapeutic strategies to improve patient outcomes is crucial. The immune system plays an integral role in the body’s response to breast cancer and modulating this immune response through immunotherapy is a promising therapeutic option. Although immune checkpoint inhibitors were recently approved for the treatment of breast cancer patients, not all patients respond to immune checkpoint inhibitors as a monotherapy, highlighting the need to better understand the biology underlying patient response. Additionally, as radiotherapy is a critical component of breast cancer treatment, understanding the interplay of radiation and immune checkpoint inhibitors will be vital as recent studies suggest that combined therapies may induce synergistic effects in preclinical models of breast cancer. This review will discuss the mechanisms supporting combined approaches with radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Moreover, this review will analyze the current clinical trials examining combined approaches of radiotherapy, immunotherapy, chemotherapy, and targeted therapy. Finally, this review will evaluate data regarding treatment tolerance and potential biomarkers for these emerging therapies aimed at improving breast cancer outcomes.

show abstract

Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy

Cited by 5 publications

References 83 publications

Current Challenges and Future Directions in the Management of Inflammatory Breast Cancer: A Review

Current Challenges and Future Directions in the Management of Inflammatory Breast Cancer: A Review

Influence of Macrophages on Vascular Invasion of Inflammatory Breast Cancer Emboli Measured Using an In Vitro Microfluidic Multi-Cellular Platform

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer

Contact Info

Product

Resources

About